Examining the Influence of Cardiovascular Outcome Trials: Is It the Heart of Diabetes?


To better understand type 2 diabetes management, you have to understand cardiovascular outcome trials (CVOTs). This interactive session will explore the unique properties, A1C-lowering effects, and CVOTs of dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium–glucose cotransporter 2 inhibitors. Using the data, participants will be able to better advise their patients on diabetes management and evaluate future CVOTs.

This activity is approved for Board Certified Ambulatory Care Pharmacist (BCACP) recertification credit.

Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to:

  1. Evaluate the potential benefits of antidiabetic drug therapy beyond A1C-lowering effects.
  2. Summarize the results of cardiovascular outcome trials (CVOTs) of antidiabetic drug therapy.
  3. Design an individualized evidence-based pharmacotherapeutic plan for a patient with type 2 diabetes.
  4. Recommend strategies for identifying and integrating into practice the results of new CVOT literature involving antidiabetic drug therapy.
Kristi Kelley, PharmD, BCPS, BCACP, CDE, BC-ADM
Clinical Professor
Auburn University Harrison School of Pharmacy
Melody Hartzler, PharmD, BCACP, BC-ADM
Melody Hartzler
Cedarville University School of Pharmacy
Learning Level: Level 3
Track: Pharmacist Clinical Patient Care Services, Ambulatory Care
Session Time Slot(s): 
Sunday, March 24
1:00 PM - 3:00 PM
Washington State Convention Center - Ballroom 6E
ACPE Pharmacist: 0202-0000-19-064-L01-P
CEUs Pharmacist: .2
Activity Type: